RxDoctor Payments Data

Jahdonna Isaac, MD

Dermatology · Wesley Chapel, FLNPI 1902466253

Payments from drug & device makers

$4,133in general payments, 2019–2025

Across 113 payments — averaging $36.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$945
  • Johnson & Johnson$643
  • Regeneron Healthcare Solutions, Inc.$472
  • E.r. Squibb & Sons, L.L.C.$275
  • Sun Pharmaceutical Industries Inc.$232
  • Sanofi$222
  • plus $1K from 19 others

What the payments were for

  • Food & beverage$3,92695%
  • Education$2075%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,133 in reported general payments places this provider in the 55th percentile of 1,147 dermatology providers in Florida.

See all dermatology providers in Florida

Medicare billing

Part B allowed, 2024
$73,084
Medicare patients
234
Services billed
1,250

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Skyrizi PenRisankizumab-Rzaa17$362,387
Dupixent PenDupilumab14$54,037
Fluorouracil178$14,172
ZoryveRoflumilast13$11,018
Clobetasol Propionate272$10,154
Calcipotriene12$5,805
Ketoconazole286$3,743
Triamcinolone Acetonide274$3,478
Clotrimazole101$2,761
Fluocinonide44$2,350
Clindamycin Phosphate49$2,144
Doxycycline Hyclate157$1,920
Metronidazole39$1,390
Mupirocin205$1,341
Ammonium Lactate28$703

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Arcutis Biotherapeutics, Inc.Zoryve$56$11,01813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,147 dermatology providers in Florida.

Other dermatology in Wesley Chapel

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →